| abstract |
Novel 2H-1-benzopyran-2-ones (coumarin derivatives) of general formula (I), and their addition compounds with physiologically tolerable acids, are disclosed. In formula (I): X is an alkylene group having 2-5 C-atoms, or a 2-hydroxypropylene group; Y is a nitrogen atom, a CH group, a COH group, or a carbon atom; R?1 is a phenyl, benzhydryl, benzhydrylidene, benzyl, diphenylhydroxymethyl, pyridinyl or pyrimidinyl residue which is optionally substituted with one or two C1?-C5? alkyl groups, one or two halogen atoms, halogen and at the same time C1?-C5? alkyl, perfluoralkyl having 1-3 C-atoms, C1?-C5? alkoxy, methylendioxy, hydroxy or nitro; R?2 is a straight-chained or branched alkyl group having 1-5 C-atoms, or a cycloalkyl group having 4-6 C-atoms; R?3 is a hydrogen atom, an alkyl group having 1-4 C-atoms, or phenyl; R?4 is a hydrogen atom, an alkyl group having 1-4 C-atoms, a phenyl group or a trifluoromethyl group, or R?3 and R?4 together represent a polymethylene chain -(CH2?)n?-, in which n is 3 or 4. Methods for manufacturing these compounds, and new intermediate products and methods of manufacture thereof are also disclosed. The novel coumarin derivatives have neuro-protective and anti-allergic properties. Medicaments containing these compounds are also described. |